Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brimonidine + pilocarpine is a combination ophthalmic drug composed of two active ingredients, brimonidine and pilocarpine, both of which are used to lower intraocular pressure in conditions such as open-angle glaucoma and ocular hypertension. Brimonidine is an alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow, thereby lowering intraocular pressure. Pilocarpine is a cholinergic (muscarinic) receptor agonist that induces miosis (pupil constriction) and increases trabecular meshwork outflow of aqueous humor. The combination leverages complementary mechanisms to enhance intraocular pressure reduction compared to monotherapy with either agent alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on brimonidine + pilocarpine.